1,2-distearoyllecithin has been researched along with Diarrhea in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
1 other study(ies) available for 1,2-distearoyllecithin and Diarrhea
Article | Year |
---|---|
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |